Ted Laffkas

Ted Laffkas is a Therapeutic Area Manager specializing in Multiple Sclerosis and Neuromyelitis Optica at Genentech, where they have launched significant therapies including Ocrevus and Enspryng. With over 20 years of clinical sales experience in neurology, Ted has consistently ranked in the top 15% of sales consultants and has received multiple prestigious awards for their achievements. Previously, they held key positions at companies such as Bristol-Myers Squibb, Regeneron Pharmaceuticals, and Bayer Pharmaceuticals, where they successfully managed product launches and built strong market presence for multiple therapies. Ted continues to pursue a Bachelor of Science in Finance at George Mason University.